Silent Inactivation of Asparaginase in Japan: Results of the Prospective ALL-ASP19 Trial

Overview

Journal Int J Hematol

Specialty Hematology

Date 2024 Sep 30

PMID 39347942

Authors

Hidemi Shimonodan

Kimiyoshi Sakaguchi

Takashi Ishihara

Yasuhiro Okamoto

Takuro Nishikawa

Dai Keino

Reo Tanoshima

Souichi Suenobu

Affiliations

Soon will be listed here.

Abstract

Silent inactivation (SI) of L-asparaginase (ASP) is a phenomenon by which a neutralizing antibody for ASP (AAA) decreases ASP activity (ASA) in patients without a clinical allergy to ASP. Acute lymphoblastic leukemia (ALL) has a poor prognosis in patients with SI. Therefore, measurement of ASA levels, not AAA levels, is needed to identify patients with SI. We herein report the results of the prospective clinical trial ALL-ASP19, the first study in Japan to measure ASA and AAA to identify patients with SI. A total of 110 newly diagnosed ALL patients were enrolled, and ASA levels were measured three times during ALL treatment. Besides the 12 patients who discontinued the study, 32 were excluded due to inappropriate frequency and timing of ASA measurements and inappropriate ASP dosing. The remaining 66 patients were analyzed, and 3 patients with SI (4.5%) were identified. The incidence of SI is lower in Japan than in other countries. AAA was detected in all patients with SI, but four of the seven patients with AAA did not develop SI. Clinical characteristics did not significantly differ between patients with and without SI. Therefore, ASA levels must be measured to identify patients receiving insufficient ASP treatment.

References

Malard F, Mohty M . Acute lymphoblastic leukaemia. Lancet. 2020; 395(10230):1146-1162. DOI: 10.1016/S0140-6736(19)33018-1. View

van der Sluis I, Vrooman L, Pieters R, Baruchel A, Escherich G, Goulden N . Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation. Haematologica. 2016; 101(3):279-85. PMC: 4815719. DOI: 10.3324/haematol.2015.137380. View

Vrooman L, Stevenson K, Supko J, OBrien J, Dahlberg S, Asselin B . Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer.... J Clin Oncol. 2013; 31(9):1202-10. PMC: 3595424. DOI: 10.1200/JCO.2012.43.2070. View

Koh K, Kato M, Saito A, Kada A, Kawasaki H, Okamoto Y . Phase II/III study in children and adolescents with newly diagnosed B-cell precursor acute lymphoblastic leukemia: protocol for a nationwide multicenter trial in Japan. Jpn J Clin Oncol. 2018; 48(7):684-691. PMC: 6022563. DOI: 10.1093/jjco/hyy071. View

Sato A, Hatta Y, Imai C, Oshima K, Okamoto Y, Deguchi T . Nelarabine, intensive L-asparaginase, and protracted intrathecal therapy for newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults (ALL-T11): a nationwide, multicenter, phase 2 trial including randomisation in the very.... Lancet Haematol. 2023; 10(6):e419-e432. DOI: 10.1016/S2352-3026(23)00072-8. View

Asselin B, Whitin J, Coppola D, Rupp I, Sallan S, Cohen H . Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol. 1993; 11(9):1780-6. DOI: 10.1200/JCO.1993.11.9.1780. View

Fernandez C, Cai X, Elozory A, Liu C, Panetta J, Jeha S . High-throughput asparaginase activity assay in serum of children with leukemia. Int J Clin Exp Med. 2013; 6(7):478-87. PMC: 3731178. View

Wang B, Hak L, Relling M, Pui C, Woo M, Storm M . ELISA to evaluate plasma anti-asparaginase IgG concentrations in patients with acute lymphoblastic leukemia. J Immunol Methods. 2000; 239(1-2):75-83. DOI: 10.1016/s0022-1759(00)00182-4. View

Woo M, Hak L, Storm M, Sandlund J, Ribeiro R, Rivera G . Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol. 2000; 18(7):1525-32. DOI: 10.1200/JCO.2000.18.7.1525. View

10.

Erwin E, Custis N, Satinover S, Perzanowski M, Woodfolk J, Crane J . Quantitative measurement of IgE antibodies to purified allergens using streptavidin linked to a high-capacity solid phase. J Allergy Clin Immunol. 2005; 115(5):1029-35. DOI: 10.1016/j.jaci.2004.12.1131. View

11.

Kanda Y . Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2012; 48(3):452-8. PMC: 3590441. DOI: 10.1038/bmt.2012.244. View

12.

Ishida H, Imamura T, Tatebe Y, Ishihara T, Sakaguchi K, Suenobu S . Impact of asparaginase discontinuation on outcomes of children with acute lymphoblastic leukaemia receiving the Japan Association of Childhood Leukaemia Study ALL-02 protocol. Br J Haematol. 2023; 201(6):1200-1208. DOI: 10.1111/bjh.18745. View

13.

Gupta S, Wang C, Raetz E, Schore R, Salzer W, Larsen E . Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. J Clin Oncol. 2020; 38(17):1897-1905. PMC: 7280050. DOI: 10.1200/JCO.19.03024. View

14.

Panosyan E, Seibel N, Martin-Aragon S, Gaynon P, Avramis I, Sather H . Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961. J Pediatr Hematol Oncol. 2004; 26(4):217-26. DOI: 10.1097/00043426-200404000-00002. View

15.

Muller H, Beier R, Loning L, Dorffel W, Maass E, Muller-Weihrich S . Pharmacokinetics of native Escherichia coli asparaginase (Asparaginase medac) and hypersensitivity reactions in ALL-BFM 95 reinduction treatment. Br J Haematol. 2001; 114(4):794-9. DOI: 10.1046/j.1365-2141.2001.03009.x. View

16.

Ahlke E, Nowak-Gottl U, Werber G, Borste H, Wurthwein G, Jurgens H . Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia. Br J Haematol. 1997; 96(4):675-81. DOI: 10.1046/j.1365-2141.1997.d01-2089.x. View

17.

Kloos R, Pieters R, Jumelet F, de Groot-Kruseman H, van den Bos C, van der Sluis I . Individualized Asparaginase Dosing in Childhood Acute Lymphoblastic Leukemia. J Clin Oncol. 2020; 38(7):715-724. DOI: 10.1200/JCO.19.02292. View

18.

Salzer W, Bostrom B, Messinger Y, Perissinotti A, Marini B . Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia. Leuk Lymphoma. 2017; 59(8):1797-1806. DOI: 10.1080/10428194.2017.1386305. View

19.

Riccardi R, Holcenberg J, Glaubiger D, WOOD J, Poplack D . L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans. Cancer Res. 1981; 41(11 Pt 1):4554-8. View

20.

Avramis V, Sencer S, Periclou A, Sather H, Bostrom B, Cohen L . A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood. 2002; 99(6):1986-94. DOI: 10.1182/blood.v99.6.1986. View